e-Drug3D

305

BETAMETHASONE ACETATE


INN
BETAMETHASONE ACETATE

(has an active metabolite)

cas 987-24-6
CLASS

DERMATOLOGICALS
GLUCOCORTICOID
ANTIPSORIATIC
ANTIINFLAMMATORY
CORTICOSTEROID
ANTIPRURITIC
VASOCONSTRICTIVE PROPERTIES

ROUTE (list)

INJECTION

ATC code

A07EA04
C05AA05
D07AC01
D07XC01
H02AB01
R01AD06
R03BA04
S01BA06
S01CB04
S02BA07
S03BA03
D07CC01
S01CA05
S03CA06
D07BC01
S01BB04

PK parameters

Solubility

PRACTICALLY INSOLUBLE IN WATER


Target

TARGET GLUCOCORTICOID RECEPTOR

DrugCentral

Glucocorticoid receptor UNIPROT P04150 NR3C1

Download SDF file 21-Acetoxy-9.alpha.-fluoro-11.beta.,17.alpha.-dihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione

Formula:
C24H31FO6

Calculated chemical properties:

MW 434.49
NB_atoms 31
XLogP 2.47
PSA 85.632
NB_HD 2
NB_HA 6
fsp3 0.71
Lipinski(0=no;1=yes) 1

FDA
NDA 014602 (label) INN (BETAMETHASONE ACETATE ; BETAMETHASONE SODIUM PHOSPHATE) CELESTONE SOLUSPAN (ORGANON) APPROVAL= AP YEAR= 1965
NDA 090747 (pdf not found) INN (BETAMETHASONE ACETATE ; BETAMETHASONE SODIUM PHOSPHATE) BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE (AM REGENT) APPROVAL= AP YEAR= 2009
NDA 077838 (pdf not found) INN (BETAMETHASONE ACETATE ; BETAMETHASONE SODIUM PHOSPHATE) BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE (HIKMA) APPROVAL= AP YEAR= 2023

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL

e-Drug3D

304

BETAMETHASONE

DISCONTINUED


INN
BETAMETHASONE

(is an active metabolite)

cas 378-44-9
CLASS

DERMATOLOGICALS
GLUCOCORTICOID
ANTIPSORIATIC
ANTIINFLAMMATORY
CORTICOSTEROID
ANTIPRURITIC
VASOCONSTRICTIVE PROPERTIES

ROUTE (list)

ORAL TOPICAL

ATC code

A07EA04
C05AA05
D07AC01
D07XC01
H02AB01
R01AD06
R03BA04
S01BA06
S01CB04
S02BA07
S03BA03
D07CC01
S01CA05
S03CA06
D07BC01
S01BB04

PK parameters

VD 84.5 LITER (65 KILOGRAM)
Cl 10.9 LITER / HOUR (65 KILOGRAM)
PPB 64 PERCENT
t1/2 5.6 HOUR

Target

TARGET GLUCOCORTICOID RECEPTOR

DrugCentral

Glucocorticoid receptor UNIPROT P04150 NR3C1

Download SDF file (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

Formula:
C22H29FO5

Calculated chemical properties:

MW 392.45
NB_atoms 28
XLogP 1.90
PSA 80.652
NB_HD 3
NB_HA 5
fsp3 0.73
Lipinski(0=no;1=yes) 1

FDA
NDA 014762 (pdf not found) INN (BETAMETHASONE) CELESTONE (SCHERING) APPROVAL= - YEAR= 0 DISCONTINUED
NDA 012657 (pdf not found) INN (BETAMETHASONE) CELESTONE (SCHERING) APPROVAL= AP YEAR= 1961 DISCONTINUED
NDA 014215 (label) INN (BETAMETHASONE) CELESTONE (MERCK SHARP DOHME) APPROVAL= AP YEAR= 1964 DISCONTINUED

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL